Kate Haviland, Blueprint Medicines CEO

What bear mar­ket? Blue­print lines up $1.25B to ex­pand la­bels, maybe tack on more drugs

As it works to pad the case for ex­pand­ing its Ay­vak­it and Gavre­to la­bels, Blue­print Med­i­cines has lined up $1.25 bil­lion in fund­ing, with some of that mon­ey seem­ing­ly ear­marked for ac­qui­si­tions or pipeline ex­pan­sion projects.

Fol­low­ing the likes of BioCryst, Cy­to­ki­net­ics and Mor­phoSys, Blue­print is aim­ing to mon­e­tize the roy­al­ties of its RET+ non-small cell lung can­cer and thy­roid can­cer drug Gavre­to with Roy­al­ty Phar­ma. The in­vest­ment group will dole out $175 mil­lion up­front and might tack on an­oth­er $165 mil­lion in biobucks as part of Blue­print’s roy­al­ties re­ceiv­able from net sales of the drug by Roche out­side the US, sans Chi­na.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.